Because these imbalances contribute to many different diseases, we believe our technology will have clinical application beyond neurological disorders.
Our technology platform applies physics to create a new class of drug candidates with the potential to treat a range of chronic and acute neurological disorders. The technology uses novel fluid dynamics, based on Taylor-Couette-Poiseuille (TCP) flow, to generate bioactive therapeutics.
Our lead drug candidate, RNS60, uniquely combines saline and oxygen to produce a drug that has been the subject of over a dozen peer-reviewed scientific publications. RNS60 has been shown to be a promising therapeutic candidate with efficacy in multiple preclinical models of disease and is now in Phase II of clinical testing for stroke and ALS.